DocGo posted a $29.7 million net loss in Q3 2025 due to impairment charges and reduced revenue from migrant-related programs. However, excluding those effects, core revenue grew and operational metrics showed strong volume gains. Adjusted EBITDA was negative, but the company maintained strong liquidity and reaffirmed forward guidance.

DocGo reported a significant decline in total revenue for Q2 2025, primarily due to the planned wind-down of migrant-related programs. Despite this, the company increased its cash balance and made progress in expanding its payer and provider business, signing new contracts across all business verticals. The net loss widened compared to the previous year, and adjusted EBITDA turned negative.

DocGo reported a significant decrease in revenue and a net loss in the first quarter of 2025, primarily due to the planned wind-down of migrant-related programs. The company updated its full-year 2025 guidance downward, removing non-migrant municipal population health revenue, while highlighting growth in its Medical Transportation and Payer & Provider businesses.

DocGo's fourth quarter 2024 revenue decreased to $120.8 million from $199.2 million in the prior year, mainly due to the wind-down of migrant-related programs. The company reported a net loss of $7.6 million for the quarter, compared to a net income of $8.0 million in Q4 2023. Full-year 2024 revenue was $616.6 million, with a GAAP gross margin of 32.1%.

DocGo reported a decrease in revenue due to the planned wind down of migrant-related programs, but net income and adjusted EBITDA increased. The company expanded its geographic footprint on the West Coast and saw strong demand for its care gap closure programs.

DocGo reported a strong second quarter with a 31% increase in total revenue compared to the previous year. Net income increased significantly, and the company raised its cash flow from operations guidance for the full year.

DocGo reported a strong first quarter in 2024, marked by a 70% increase in total revenue, reaching $192.1 million, and a significant improvement in net income, which rose to $10.6 million compared to a net loss in the previous year. The company also revised its 2024 revenue guidance due to the accelerated wind-down of migrant-related services, while maintaining a positive outlook for its base business.

DocGo reported a strong fourth quarter with total revenues of $199.2 million, an 83% increase compared to the previous year. Net income increased by 13% to $8.0 million, and adjusted EBITDA saw a substantial rise of 232% to $22.6 million. The company's full-year revenue increased by 42% to $624.2 million.

DocGo reported a strong third quarter with a 79% increase in revenue compared to Q3 2022, driven by gains in nearly all business and project lines. Net income and Adjusted EBITDA also saw significant increases. The company raised its full-year 2023 revenue and adjusted EBITDA guidance.

DocGo announced record second-quarter results, driven by strong growth in core markets and high demand for proactive healthcare programs. The company increased its full-year revenue and adjusted EBITDA guidance to $540-$550 million and $48-$53 million, respectively.

DocGo reported its Q1 2023 results, highlighting continued operational execution and growth in the RFP channel. The company also signed agreements to expand its remote patient monitoring and chronic care management services.

DocGo reported full-year revenue of $440.5 million, a 38% increase compared to 2021. The company introduced full-year 2023 revenue guidance of $500-$510 million and adjusted EBITDA guidance of $45-$50 million.

DocGo reported a strong Q3 2022 with revenue reaching $104.3 million, a 22% increase year-over-year. The company raised its full-year 2022 revenue and adjusted EBITDA guidance. CEO Stan Vashovsky announced his retirement effective December 31st, with Anthony Capone named as the new CEO.

DocGo reported a strong second quarter with revenue of $109.5 million, a 76% increase year-over-year. The company's performance was driven by new contracts and expansion, which offset the decline in COVID-19 testing revenue. DocGo also raised its full-year 2022 guidance.

DocGo reported a strong first quarter in 2022, with revenue increasing by 137% compared to the previous year. The company is transitioning from COVID-related services to longer-term, non-COVID work and expanding its geographic reach. They generated strong net income and cash flow, and expect to see continued improvements in profitability over time.